Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The ITC found that "multiple bad actors" have been importing or selling knockoff copies of Lilly's tirzepatide.

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...